Related Experiment Video
Updated: Sep 8, 2025

Characterization of G Protein-coupled Receptors by a Fluorescence-based Calcium Mobilization Assay
Published on: July 28, 2014
GPR17 - orphan G protein-coupled receptor with therapeutic potential
Michael Lewash1, Evi Kostenis2, Christa E Müller1
1PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
The G protein-coupled receptor (GPCR) GPR17 shows promise for treating multiple sclerosis (MS) by enabling remyelination. New research and drug candidates like PTD802 offer hope for MS therapies and other neurodegenerative diseases.
Area of Science:
- Neuroscience
- Pharmacology
- Structural Biology
Background:
- The orphan G protein-coupled receptor (GPCR) GPR17 is a potential therapeutic target for multiple sclerosis (MS).
- Its physiological agonist is currently unknown, but blocking GPR17 promotes remyelination.
- Recent advancements include the development of selective GPR17 tool compounds and antagonists.
Purpose of the Study:
- To review recent developments in GPR17 research.
- To highlight GPR17 as a drug target for multiple sclerosis and neurodegenerative diseases.
- To discuss the implications of the new GPR17 cryo-EM structure for drug design.
Main Methods:
- Review of recent scientific literature and patent filings.
- Analysis of emerging GPR17 tool compounds and drug candidates.
- Discussion of the newly determined GPR17 cryo-electron microscopy (cryo-EM) structure.
Main Results:
- Potent and selective GPR17 tool compounds are now available.
- The GPR17 antagonist PTD802 is the first clinical candidate for MS therapy.
- The GPR17 cryo-EM structure has been determined, aiding structure-based drug design.
Conclusions:
- GPR17 blockade is a promising therapeutic strategy for MS, potentially extending to other neurodegenerative diseases.
- The availability of selective antagonists and structural data accelerates drug development for GPR17.
- Further clinical studies are anticipated to explore GPR17's therapeutic potential.
More Related Videos
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Related Concept Videos
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
G-protein Coupled Receptors
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical,...
GPCR Desensitization
GPCRs Regulate Adenylyl Cylase Activity
Activation and Inactivation of G Proteins